patent on semaglutide expires next year: Novo Nordisk faces tough competition in the Chinese obesity market Brazilian federal court denies semaglutide

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

The researchers noted that many of the studies were too small, short, and poorly designed to draw any real conclusions about the supplements being investigated

men to initiate a GLP-1, but the difference was not statistically significant

According to UAB clinicians, patients are presenting with dangerously low blood sugar, severe nausea, and pancreatitisoften the result of unsupervised use or improper titration

Your provider needs to assess whether your post-cholecystectomy gut physiology can tolerate these additional changes without triggering diarrhea, fat malabsorption, or other gastrointestinal complications